IPO - Profile

Adagene Inc.

Health Care > Major Pharmaceuticals

ADAG

Summary

We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our immunotherapy pipeline. These features enable our novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. We have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$19.00 7,350,000 Positive High 69.87%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • PricewaterhouseCoopers Zhang Tian LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 08 Feb, 2021

Offer 09 Feb, 2021

Look Ahead

Lock Up Expiry Aug 09, 2021

IPO Terms

Offer Price $19.00
Offer Size 7M

Market Sentiments

Stock Price